期刊文献+

氧化石墨烯负载多柔比星对多发性骨髓瘤细胞的杀伤作用

Graphene oxide loaded with doxorubicin: a killer for multiple myeloma cells
下载PDF
导出
摘要 背景:研究发现氧化石墨烯对正常细胞的毒性比较低,但有关氧化石墨烯负载多柔比星抗肿瘤药物后对恶性肿瘤细胞是否有影响的研究不多。目的:探讨氧化石墨烯负载多柔比星对多发性骨髓瘤细胞的杀伤作用。方法:取对数生长期人多发性骨髓瘤细胞株RPMI8226,分4组培养,其中3组分别加入氧化石墨烯负载多柔比星、多柔比星、氧化石墨烯,对照组不干预。培养24 h,CCK-8方法检测细胞活性,流式细胞仪检测细胞周期和细胞凋亡。结果与结论:(1)对照组细胞质透亮清晰,多数为饱满形态;氧化石墨烯组细胞质较透亮,少数细胞出现皱缩;多柔比星组细胞形态不均一,细胞出现皱缩,有凋亡小体出现;氧化石墨烯负载多柔比星组细胞体积明显缩小,皱缩较明显,出现凋亡小体;(2)氧化石墨烯负载多柔比星组、多柔比星组、氧化石墨烯组细胞存活率均低于对照组(P<0.05),氧化石墨烯负载多柔比星组细胞存活率明显低于氧化石墨烯组(P<0.05);(3)氧化石墨烯负载多柔比星组、多柔比星组细胞凋亡率高于氧化石墨烯组、对照组(P<0.05);(4)4组间细胞周期比较差异无显著性意义;(5)结果表明,氧化石墨烯负载多柔比星具有较强的毒性作用,可诱导人多发性骨髓瘤细胞凋亡。 BACKGROUND: Cytotoxicity of graphene oxide to normal cells is relatively low, but whether graphene oxide loaded with doxorubicin has some effects on malignant cells is rarely reported. OBJECTIVE: To explore the cytotoxicity of graphene oxide loaded with doxorubicin on multiple myeloma cells. METHODS: Multiple myeloma cell line RPMI8226 in logarithmic phase was selected, cultured and divided into four groups, including graphene oxide loaded with doxorubicin, doxorubicin and graphene oxide groups as well as control group with no intervention. After 24 hours of culture, the cell activity was detected by cell counting kit-8 method, and the cell cycle and apoptosis were detected using flow cytometry. RESULTS AND CONCLUSION: Plump-shaped cells with translucent and clear cytoplasm were found in the control group; cells with relatively translucent cytoplasm, and even a few shrunken cells appeared in the graphene oxide group; cellular morphology was in a heterogeneity, apoptotic bodies appeared in the doxorubicin group; the cells was significantly reduced in size, presenting more obvious shrinkage and apoptotic bodies in the group of graphene oxide loaded with doxorubicin. The cell survival rate in the graphene oxide loaded with doxorubicin, doxorubicin and graphene oxide groups was significantly lower than that in the control group(P 〈0.05), and this indicator was significantly lower in the group of graphene oxide loaded with doxorubicin than the graphene oxide group(P 〈0.05). The apoptotic rate in the group of graphene oxide loaded with doxorubicin and doxorubicin group was significantly higher than those in the graphene oxide and control groups(P〈 0.05), respectively. Additionally, there were no significant differences in the cell cycle among groups. These results show that graphene oxide loaded with doxorubicin has a stronger cytotoxicity, and can induce apoptosis in human multiple myeloma cells.
出处 《中国组织工程研究》 CAS 北大核心 2016年第38期5636-5641,共6页 Chinese Journal of Tissue Engineering Research
  • 相关文献

参考文献39

  • 1Takamatsu Y, Sunami K, Muta T, et aI.Kyushu Hematology Organization for Treatment Study Group(K-HOT). Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study.lnt J Hematol. 2013;98(2):179-185.
  • 2Shahil KM,Alexander A.Thermal properties of graphene and multilayer graphene: Applications in thermal interlace materials.Solid State Commun. 2012 152(15): 1331-1340.
  • 3Lian P, Zhu X,Liang S,et aI.High reversible capacity of SnOi/graphene nanocomposite as an anode material for lithium-ion batteries.Electrochim Acta.2011 ;56: 4532-4539.
  • 4Gao Y, Li Y, Zhang Let at,Adsorption and removal of tetracycline antibiotics from aqueous solution by graphene oxide.J Colloid Interface Sci. 2012;368(1):540-546.
  • 5Kwak YH,Choi DS,Kim YN,et al.Flexible glucose sensor using CVD-grown graphene-based field effect transistor.Biosens Bioelectron.2012;37(1 ):82-87.
  • 6Premkumar T, Geckeler KE.Graphene-DNA hybrid materials:Assembly, applications,and prospects. Prog Polym Sci.2012;37(4):515-529.
  • 7. Li Y, Liu Y, Fu Y, et al.The triggering of apoptosis in macrophages by pristine graphene through the MAPK and TGF-beta signaling pathways.Biomaterials. 2012; 33(2):402-411.
  • 8Zhou H,Zhao K,Li W,et al.The interactions between pristine graphene and macrophages and the production of cytokines/chemokines via TLR- and NF-KB-related signaling pathways.Biomaterials. 2012; 33(29):6933-6942.
  • 9Akhavan O,Ghaderi E,Akhavan A.Size-dependent genotoxicity of graphene nanoplatelets in human stem cells.Biomaterials.2012;33(32):8017-8025.
  • 10Chang Y, Yang ST, Liu JH,et alan vitro toxicity evaluation of graphene oxide on A549 cells.Toxicol Lett.2011 ;200(3):201-210.

二级参考文献88

  • 1唐雪娟,任莉.低剂量沙利度胺联合常规化疗治疗多发性骨髓瘤的临床分析[J].中国生化药物杂志,2014,34(4):113-115. 被引量:21
  • 2陈腾,茹小鹏,顾珊智,韩卫,贾晓俤,高雅,张秦初.药物不良事件及其法医学鉴定[J].法医学杂志,2007,23(1):26-29. 被引量:5
  • 3SLINGEKLAND M, GUCHELAAR HJ, GELDERBLOM H. Li-posomal drug formulations in cancer therapy : 15 years along theroad [ J ]. Drug Discov Today ,2012, 17(3-4): 160 -166.
  • 4ALLEN TM, HANSEN CB,DEMENEZES DEL. Pharmacokinet-ics of long cir-culating liposomes[ J]. Adv Drug Deliv Rev, 1995,16(2 - 3 ) : 267 -284.
  • 5NORTHFELT DW, MARTIN FJ,WORKING .,et al. Doxorubi-cin encapsu-lated in liposomes containing surface bound polyethy-lene glycol : plarmackinetics,tumor localization and safety in pa-tients with AIDS-related Kaposi, sarcoma [ J ]. J Clin Pharmacol,1996,36(1) ; 55 -63.
  • 6RIFKIN RM, GREGORY SA, MOHRBACHER AN,ef al. Pegy-lated liposomal doxorubicin, vincris-tine, and dexamethasoneprovide significant reductionin toxicity compared with doxorubi-cin ,vincristine, and dexamethasone in patients with newly diag-nosedmultiple myeloma[ J]. Cancer,2006 ,106(4) ;848 - 858.
  • 7KESTERSON JP,ODUNSI K, LELE S,et al. Highcumulativedoses of pegylated liposomal doxorubicin are notassociated withcardiac toxicity in patients with gynecologicmalignancies [ J ].Chemother, 2010, 56(2) : 108 -111.
  • 8O,BRIEN ME,WIGLER N,INBAR M, et al. Reducedcardio-toxicity and comparable efficacy in a phase III trial ofpegylated li-posomal doxorubicin HCl ( CAELYX/Doxil) versus conventionaldoxorubicin for first-line treatment ofmetastatic breast cancer[ J ].Ann Oncol, 2004,15(3) : 440 -449.
  • 9ANNE M , JEREMY W, MICHAEL L,et al. A phase II nonran-domized open-label study of liposomal daunorubicin ( DaunoX-ome) in advanced soft tissue sarcoma [ J ]. Sarcoma, 2006,1(1):1 -5.
  • 10STATHOPOULOS GP.ANTONIOU D , DIMITROULIS J,et al.Liposomal cisplatin combined with paclitaxel versus cisplatin andpaclitaxel in non-small-cell lung cancer: a randomized phase IIImulticenter trial[ J]. Ann Oncol,2010,21(11) : 2227 -2232.

共引文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部